Our core aim is to provide engineered antibodies for all. This means giving access to the whole R&D community, not just a select few. Our main services cover: antibody engineering and class switching, antibody expression and hybridoma sequencing.
Read More >>
25th April 2018 - We've launched our murine CD47-PD-L1 bispecific antibody in a world exclusive for the reagents market. … More >>
